Minhua Chu, Managing Partner at TransitionValue Partner, shared a post on X:
“Rui Therapeutics (Shenzhen) completed a Series A financing exceeding RMB 200 million.
This round of financing was jointly led by Shenzhen Capital Group, Hengqin Venture Capital under Zhuhai Science and Technology Industry Group, and Green Pine Capital.
Rui Therapeutics was established in 2021 and is a platform company specializing in next-generation I&I new drug development.
Rui Therapeutics has established a technology platform centered on CAR-NK in the I&I field and has also developed allogeneic ex vivo CAR-T and TCE multi-antibody platforms.
Its pipeline addresses autoimmune diseases, inflammatory diseases, fibrosis, and other clinical indications with unmet needs.
Lead candidate CAR-NK KN5501 for SLE just received IND approval in China on 4 September.”
More posts featuring Minhua Chu.